http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101734652-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate | 2015-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-101734652-B1 |
titleOfInvention | Gene related to Doxorubicin resistance and use thereof |
abstract | The present invention relates to anticancer drug resistance-related genes and uses thereof. The composition according to the present invention contains as an active ingredient FLNA (Filamin A) or NLRP13 (NOD-like receptor family pyrin domain 13) protein or a gene encoding the protein, and is capable of acquiring resistance to an anticancer drug by inhibiting expression of the gene Experimental confirmation of the increase in survival rate of cancer cells is expected to provide more effective treatment for cancer treatment. |
priorityDate | 2015-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 743.